Multi-year Revenue GrowthSugi’s sustained top-line expansion, with a pronounced acceleration in 2025 and continuing in 2026, indicates expanding store sales and prescription volumes. Durable revenue momentum supports scale benefits, steadier cash generation and strategic reinvestment over the coming 2–6 months.
Improved Cash GenerationA meaningful rebound in operating and free cash flow in 2026 materially strengthens near-term liquidity and funding capacity. Improved cash conversion increases ability to fund capex, service debt, and support store expansion or working capital without immediate external financing.
Defensive Pharmacy Business ModelCore dispensing pharmacy revenues are anchored to Japan’s national health insurance system, generating recurring, less-cyclical cash flows. The integrated drugstore network enables cross-selling of OTC and daily goods, reinforcing customer retention and steady demand over time.